Added to YB: 2026-10-09
Pitch date: 2026-10-04
MGNX [bullish]
MacroGenics, Inc.
-9.32%
current return
Author Info
No bio for this author
Company Info
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Market Cap
$232.2M
Pitch Price
$3.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.63
P/E
-2.28
EV/Sales
0.54
Sector
Biotechnology
Category
special_situation
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - MacroGenics, Inc.
MGNX (hold): MacroGenics offers multiple value pockets through a HER2 commercial component and a broader antibody and bispecific pipeline. The strategic case centers on asset-level partnering, as buyers can license, co-develop or acquire individual programs without purchasing the company. That structure preserves program-level optionality but limits corporate-bid urgency, particularly without a single clear must-own asset.
Read full article (1 min)